Navigation Links
Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma
Date:7/24/2014

of emerging generics and biosimilar omalizumab: Interviewed EU5 payers agree that the use of generic or branded-generic versions of LABA/ICS FDCs, Seretide and Symbicort (AstraZeneca), and biosimilar omalizumab are likely to be promoted. Surveyed pulmonologists indicate that concerns regarding safety and bioequivalency of biosimilar omalizumab to Xolair (Genentech/Novartis) need to be addressed before they would consider prescribing the drug.

 

Comments from Decision Resources Group Analyst Eun-Jin Yang, Ph.D.:

  • "In these times of austerity, payers across the EU5 emphasize that for an emerging therapy to secure favorable terms in reimbursement and pricing negotiations, the drug has to demonstrate superiority in efficacy in head-to-head trials against an appropriate comparator. Thus, given the non-inferiority efficacy profile in asthma indication, Relvar's pricing will be key for its favorable placement in the treatment guideline and for driving uptake."
  • "Even though payers across the EU5 have only a modest cost-saving expectation for generic LABA/ICS FDCs and for biosimilar omalizumab, they indicate a strong interest in promoting the usage of these agents, particularly for treatment-naive patients. However, they are less enthusiastic for biosimilar omalizumab, likely due to the lack of experience with biosimilars to date which contributes to payer and physician uncertainty regarding biosimilar omalizumab's safety and bioequivalency to Xolair. This could be mitigated by biosimilar omalizumab demonstrating a robust safety and bioequivalency profile compared to Xolair."

 

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at '/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
4. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
5. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
6. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
7. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
8. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
9. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. (NYSE: ... is providing innovative evidence-based solutions for the treatment of ... its preliminary response to the Patent Trial and Appeals ... inter partes review (IPR), filed by a unit of ... in U.S. Patent No. 8,359,102 (the ,102 patent). The ,102 ...
(Date:9/1/2015)... and BRUSSELS , ... ) and UCB (Euronext Brussels: UCB) today announced ... effect of RomosozUmab Compared with Teriparatide in postmenopaUsal ... pReviously treated with bisphosphonatE therapy). The study (NCT01796301) ... difference in favor of romosozumab in the percent ...
(Date:9/1/2015)... N.J. , Sept. 1, 2015 Konica ... CS-7s Computed Radiography (CR) system, designed to deliver enterprise ... By utilizing the same Control Station as the Konica ... assured with an upgrade path from CR to DR. ... imaging to help improve workflow with unparalleled reliability and ...
Breaking Medicine Technology:Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2
... ALLENTOWN, Pa., May 8, 2012 Brainybrawn, Inc. ... that its subsidiary Sanvi Infotech Pvt. Ltd (India) has ... MCIMS ), a web based application for comprehensive information ... announced that its subsidiary Sanvi Infotech Pvt. Ltd (India) ...
... 8, 2012  eCardio Diagnostics, President and Chief Executive Officer, ... upcoming event presented by Comcast Business Class and Inc. ... event series, "Act at the Speed of Opportunity," is ... and provides attendees with information that can be used ...
Cached Medicine Technology:Brainybrawn, Inc. announces Launch of its Web based Medical College Information Management Solution (Sanvi MCIMS), as well as Receipt of Order for Its Comprehensive Restaurant Information Management Solution for Managing Chain of Restaurants (Sanvi 2Brainybrawn, Inc. announces Launch of its Web based Medical College Information Management Solution (Sanvi MCIMS), as well as Receipt of Order for Its Comprehensive Restaurant Information Management Solution for Managing Chain of Restaurants (Sanvi 3eCardio's CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc. 2
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... September as Brain Aneurysm Awareness Month , which was established by the ... , “Spreading awareness and education, and helping fund more research remains our top ...
(Date:9/2/2015)... ... September 02, 2015 , ... This Fall, as ... (BCAM), Bright Pink, a national non-profit focused on the prevention and early detection ... a campaign to educate women to be breast and ovarian self-aware and celebrate ...
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... ... Business Times discusses the hundreds of thousands of plastic surgeries conducted each year ... and reality TV for the growing numbers. Beverly Hills-based plastic surgeon Payam Jarrah-Nejad, ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Capillus82™ ... treatment of androgenic alopecia in adults, announces Miami-based medical device manufacturer, Capillus, LLC. ... also demonstrating its safety when used at home to combat hair loss. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ProRehab Physical Therapy , ... partnership with Apex Physical Therapy (Apex) is official as of August ... compassionate, and empathetic care to local residents from their combined eight locations throughout ...
Breaking Medicine News(10 mins):Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3
... Safety Project Report Makes Recommendations for System in Critical Need ... Nov. 17 Weaknesses in food safety policy, organization and ... Saintpaul, according to a report released today by the Produce ... at Georgetown University . , ...
... MYL ) today announced that its subsidiary, Mylan ... Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) ... , Fluoxetine Capsules, indicated for ... version of Eli Lilly,s Sarafem(R) Pulvules(R) Capsules. This product had ...
... procedure in which her stem cells were combined with ... , , TUESDAY, Nov. 18 (HealthDay News) -- In a ... undergone the first transplantation of a breathing passage fashioned ... researchers report. , As of now, the woman, Claudia ...
... as Chairman, Tony Strange Appointed to CEO position and Will ... , MELVILLE, N.Y., Nov. 18 /PRNewswire-FirstCall/ ... ), a leading provider of comprehensive home health services, announced ... succession plan. Effective January 1, 2009, Tony Strange will ...
... and Policy Center (NLPC), a plaintiff in the successful 1993 ... Clinton,s health care task force, today criticized Barack Obama for ... , According to NLPC President Peter ... General. His track record is not one of independence or ...
... mechanisms, scientists show , , TUESDAY, Nov. 18 (HealthDay News) ... mechanisms, according to a Washington University study that challenges ... version of the body,s response to pain. , This ... itching and pain. , Zhou-Feng Chen, of Washington University,s ...
Cached Medicine News:Health News:Salmonella Saintpaul Outbreak Exposes Food Safety Weaknesses 2Health News:Salmonella Saintpaul Outbreak Exposes Food Safety Weaknesses 3Health News:Airway Transplant Aided by Stem Cells a Medical First 2Health News:Airway Transplant Aided by Stem Cells a Medical First 3Health News:Gentiva Health Services Confirms Management Succession 2Health News:Gentiva Health Services Confirms Management Succession 3Health News:Gentiva Health Services Confirms Management Succession 4Health News:NLPC Criticizes Obama's Choice of Eric Holder for Attorney General Because of Role in Health Care Task Force Cover-Up 2Health News:Itching Not a Less Intense Form of Pain 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: